Australia's most trusted
source of pharma news
Sunday, 23 February 2025
Posted 20 February 2024 AM
Novo Nordisk's CagriSema has been crowned biopharma's most valuable R&D project in Evaluate's latest industry forecast.
The list ranks the leading 10 R&D programs by net present value (NPV) with the follow-on type 2 diabetes and obesity treatment easily taking first place with a NPV of $30.2 billion.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.